View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery Syst...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit:  With each new study, the horizon of GLP-1’s therapeutic potential expands, painting a vibrant picture of a future where a single molecule could tackle a multitude of ...

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 60+ brands within the @ (), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs,” please visi...

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Even Better?” To hear the AudioPressRelease, please visit: To view the full editorial, please visit:    It shouldn’t be surprising that analysts at Markets and Research estimate the global diabetes drug market at $63.1 billion in 2021 on its way to $82.93 billion in 2027, while th...

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-De...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 60+ brands within the  @  (), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Can Diabetes, Weight-Loss Drugs Get Even Better?”,please visit:   The prest...

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hy...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit:  In its 2021 industry report, estimated the global anti-hypertensive drugs market at $24.17 billion in 2020 on its way to reach $27.81 billion in 2025. All told, hypertension costs the country on average ann...

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Tr...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “The Power of Science to Stop a Killer,” please visit: Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More ...

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Del...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit:  The fact remains that an estimated 1.1 billion people smoked cigarettes in 2019. According to stats from the World Health Organization, a stunning 780 million people said they want to quit. As a result, people look to a multitud...

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery T...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Nicotine Surges as Smoking Sags,” please visit: Seems like yesterday people were smoking cigarettes everywhere; many people still have memories of Grandpa puffing on his Ca...

 PRESS RELEASE

Sunniva Inc. Announces Issuance of Secured Promissory Notes of its Who...

Sunniva Inc. Announces Issuance of Secured Promissory Notes of its Wholly-Owned Subsidiary, CP Logistics, LLC VANCOUVER, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Sunniva Inc. (“Sunniva”, the “Company”) (CSE:SNN) (OTC Pink Sheets:SNNVF) announced today that its wholly-owned subsidiary, CP Logistics, LLC (“CPL”), closed a non-brokered private placement of secured promissory notes (the “Notes”) on February 10, 2022, for aggregate proceeds of US$700,000. The Notes bear interest at a rate of 20% per annum, mature on January 31, 2026, and are secured against all of the assets of CPL....

 PRESS RELEASE

Sunniva Inc. Announces Financial Update

Sunniva Inc. Announces Financial Update  VANCOUVER, British Columbia, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Sunniva Inc. (“Sunniva”, the “Company”) (CSE:SNN) (OTC Pink Sheets:SNNVF) provides an update on several financing related items. The Company’s wholly-owned subsidiary, CP Logistics, LLC (“CPL”), is proposing to conduct a non-brokered private placement of up to US$1M of secured promissory notes (the “Notes”), bearing interest at a rate of 20% per annum and maturing on January 31, 2026 (the “CPL Financing”). The Notes will be secured against all of the assets of CPL. If the Arbitration (...

Los Andes Copper Ltd: 1 director

A director at Los Andes Copper Ltd maiden bought 9,100 shares at 9.720CAD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

Los Andes Copper Ltd. (TSXV: LA) – Expecting a Strong PFS

Fundamental Research Corp has issued a report entitled “Los Andes Copper Ltd. (TSXV: LA) - Expecting a Strong PFS” and dated October 1, 2021. The full report is now at

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit ...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud Noise for Investors.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit:  The market is certainly worth entering. Consider that Reportlinker.com estimates the global anti-hypertensive drugs market to be $24.37 billion in 2021 and growing 3.4% an...

 PRESS RELEASE

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension ...

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities.  To view the full publication, “Hypertension: The Silent Killer Making Loud Noise for Investors,” please visit:  Hypertension, or high blood pressure, is rampant in America. An estimat...

 PRESS RELEASE

Sunniva Announces Update on Audit and Arbitration Matters

Sunniva Announces Update on Audit and Arbitration Matters VANCOUVER, British Columbia, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sunniva Inc. (“Sunniva”, the “Company”) (CSE:SNN) (OTC Pink Sheets:SNNVF) announces an update regarding work on the audits of the Company’s financial statements for the years ended December 31, 2019 and 2020.     After implementation of its Amended and Consolidated Plan of Compromise and Arrangement and its release and discharge from its CCAA proceedings, the Company engaged MNP LLP (“MNP”), its historical auditor, to conduct financial statement audits for the years e...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch